allogeneic cd19 car-t cells

Cell therapyexperimental

Clinical trial activity

9 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2011 (NCT01497184)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • allogeneic cart-19
  • allogeneic cd19-specific t cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07113496Phase 1Aug 31, 2025Nanjing Medical University
NCT07105735Phase 1Aug 31, 2025Allorunning Therapeutics, Nanjing Medical University, Rui Therapeutics Co., Ltd
NCT07129642Early Phase 1 (Phase 1)Aug 10, 2025Fudan University
NCT05143112Phase 1/Phase 2 (Phase 2)Feb 5, 2021Shenzhen University
NCT05164042Phase 1/Phase 2 (Phase 2)Feb 5, 2021Shenzhen University
NCT03666000Phase 1/Phase 2 (Phase 2)Dec 31, 2018Precision BioSciences, Inc.
NCT02799550Phase 1Oct 1, 2015People's Liberation Army of China
NCT01362452Phase 1Dec 1, 2012University of Texas at Houston
NCT01497184Phase 1Dec 1, 2011Intrexon, University of Texas at Houston, Ziopharm
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Nanjing Medical UniversityAcademic/Hospital2212025
Shenzhen UniversityAcademic/Hospital2212021
University of Texas at HoustonAcademic/Hospital2212011
Allorunning TherapeuticsFor profit1012025
Fudan UniversityAcademic/Hospital1112025
IntrexonFor profit1012011
People's Liberation Army of ChinaGovernment1112015
Precision BioSciences, Inc.For profit1112018
Rui Therapeutics Co., LtdFor profit1012025
ZiopharmFor profit1012011
10 organizations
Page 1 / 1